Skip to main content
SpringerLink
Log in

Vraies et fausses innovations en psychiatrie

  • Chapter
Psychiatrie française / Psychiatrie en France

  • 445 Accesses

Résumé

Est-ce l’essoufflement (passager ?) de l’industrie du médicament ? L’aspiration générale à un mode de vie plus sain ? Un esprit de compé- tition et de productivisme pour soigner en 10 jours ce qui pouvait en nécessiter 90 ? Les limites de modèles théoriques qui ont maintenant près de 50 ans pour certains ? Un moment de déception ou un senti- ment d’insuffisance pour les générations qui n’ont pas connu le moment »magique« de la révolution des neuroleptiques et des anti- dépresseurs ? Ces dix dernières années ont été marquées par une pro- lifération de méthodes thérapeutiques allant des suppléments alimentaires à la pose de sonde de stimulation électrique à l’intérieur même du cerveau, en passant par des techniques de psychothérapie faisant appel à la méditation ou aux roulements d’yeux.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Ruhé HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatr 12: 331–59.

    Article  Google Scholar 

  2. Evers EA, Sambeth A, Ramaekers JG et al. (2010) The effects of acute tryptophan depletion on brain activation during cognition and emotional processing in healthy volunteers. Curr Pharm Des 16: 1998–2011.

    Article  PubMed  CAS  Google Scholar 

  3. Coppen A, Shaw DM, Farrell JP (1963) Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1 (7272): 79–81.

    Article  PubMed  CAS  Google Scholar 

  4. Parker G, Brotchie H (2011) Mood effects of the amino acids tryptophan and tyrosine:’ Food for Thought’ III. Acta Psychiatr Scand 124: 417–26.

    Article  PubMed  CAS  Google Scholar 

  5. Muldoon MF, Manuck SB, Matthews KA (1990) Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301: 309–14.

    Article  PubMed  CAS  Google Scholar 

  6. Lester D (2002) Serum cholesterol levels and suicide: a meta-analysis. Suicide Life Threat Behav Fall 32: 333–46.

    Article  Google Scholar 

  7. Muldoon MF, Manuck SB, Mendelsohn AB et al. (2001) Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 322: 11–5.

    Article  PubMed  CAS  Google Scholar 

  8. Hibbeln JR, Salem N Jr (1995) Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 62: 1–9.

    PubMed  CAS  Google Scholar 

  9. Hibbeln JR (1998) Fish consumption and major depression. Lancet 351: 1213.

    Article  PubMed  CAS  Google Scholar 

  10. Noaghiul S, Hibbeln JR (2003) Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatr 160: 2222–7.

    Article  PubMed  Google Scholar 

  11. Appleton KM, Rogers PJ, Ness AR (2010) Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 91: 757–70.

    Article  PubMed  CAS  Google Scholar 

  12. Martins JG (2009) EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 28: 525–42.

    PubMed  CAS  Google Scholar 

  13. Hibbeln JR, Nieminen LR, Blasbalg TL et al. (2006) Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 83 (6 Suppl): 1483S–1493S.

    PubMed  CAS  Google Scholar 

  14. FDA Announces Qualified Health Claims for Omega-3 Fatty Acids (2004). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ ucm108351.htm.

    Google Scholar 

  15. Rissanen T, Voutilainen S, Nyyssönen K et al. (2000) Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: the Kuopio ischaemic heart disease risk factor study. Circulation 102: 2677–9.

    Article  PubMed  CAS  Google Scholar 

  16. DeFilippis AP, Sperling LS (2006) Understanding omega-3’s. Am Heart J 151: 564–70.

    Article  PubMed  CAS  Google Scholar 

  17. Moniz E (1937) Prefrontal leucotomy in the treatment of mental disorders. Am J Psychiatry 93: 1379–85.

    Google Scholar 

  18. Bini L (1938) Experimental researches on epileptic attacks induced by the electric current. The treatment of schizophrenia: insulin, shock, cardiozol, sleep treatment. Am J Psychiatry 94 (Suppl): 172–4.

    Google Scholar 

  19. Tooth JC, Newton MP (1961) Leucotomy in England and Wales 1942-1954. Reports on public health and medical subjects. Report No.: 104. Her Majesty’s Stationery Office, London.

    Google Scholar 

  20. Andrade P, Noblesse LH, Temel Y et al. (2010) Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review. Acta Neurochir (Wien) 152: 565–77.

    Article  Google Scholar 

  21. Slotema CW, Blom JD, Hoek HW, Sommer IE (2010) Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatr 71: 873–84.

    Article  Google Scholar 

  22. Nauczyciel C, Hellier P, Morandi X et al. 2011 Assessment of standard coil positioning in transcranial magnetic stimulation in depression. Psychiatry Res 186: 232–8.

    Article  PubMed  Google Scholar 

  23. Hoogendam JM, Ramakers GM, Di Lazzaro V (2010) Physiology of repetitive transcranial magnetic stimulation of the human brain. Brain Stimul 3: 95–118.

    Article  PubMed  Google Scholar 

  24. Huerta PT, Volpe BT (2009) Transcranial magnetic stimulation, synaptic plasticity and network oscillations. J Neuroeng Rehabil 6: 7.

    Article  PubMed  Google Scholar 

  25. Cheeran B, Talelli P, Mori F et al. (2008) A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol 586(Pt 23): 5717–25.

    Article  PubMed  CAS  Google Scholar 

  26. Paulus W, Classen J, Cohen LG et al. (2008) State of the art: Pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimul 1: 151–63.

    Article  PubMed  Google Scholar 

  27. Nowak DA, Bösl K, Podubeckà J, Carey JR (2010) Noninvasive brain stimulation and motor recovery after stroke. Restor Neurol Neurosci 28: 531–44.

    PubMed  Google Scholar 

  28. Málly J, Stone TW (2007) New advances in the rehabilitation of CNS diseases applying rTMS. Expert Rev Neurother 7: 165–77.

    Article  PubMed  Google Scholar 

  29. Elger G, Hoppe C, Falkai P et al. (2000) Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 42: 203–10.

    Article  PubMed  CAS  Google Scholar 

  30. Henry TR, Bakay RA, Votaw JR et al. (1998). Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia 39: 983–90.

    Article  PubMed  CAS  Google Scholar 

  31. Rush AJ, Marangell LB, Sackeim HA et al. (2005) Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatr 58: 347–54.

    Article  Google Scholar 

  32. Sackeim HA, Brannan SK, Rush AJ et al. (2007) Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol 10: 817–26.

    Article  PubMed  CAS  Google Scholar 

  33. George MS, Aston-Jones G (2010) Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Neuropsychopharmacology 35: 301–16.

    Article  PubMed  Google Scholar 

  34. Mayberg HS, Lozano AM, Voon V et al. (2005) Deep brain stimulation for treatment-resistant depression. Neuron 45: 651–660.

    Article  PubMed  CAS  Google Scholar 

  35. Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH (2008) Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatr 64: 461–7.

    Article  Google Scholar 

  36. Malone DA Jr, Dougherty DD, Rezai AR et al. (2009) Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatr 65: 267–75.

    Article  Google Scholar 

  37. Bewernick BH, Hurlemann R, Matusch A et al. (2010) Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatr 67: 110–6.

    Article  Google Scholar 

  38. Ackermans L, Duits A, van der Linden C et al. (2011) Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain 134(Pt 3): 832–44.

    Article  PubMed  Google Scholar 

  39. Voon V, Krack P, Lang AE et al. (2008) A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain 131(Pt 10): 2720–8.

    Article  PubMed  Google Scholar 

  40. Zarate CA Jr, Singh JB, Carlson PJ et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatr 63: 856–64.

    Article  PubMed  CAS  Google Scholar 

  41. Zarate CA Jr, Singh JB, Quiroz JA et al. (2006) A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatr 163: 153–5.

    Article  PubMed  Google Scholar 

  42. Zarate C Jr, Machado-Vieira R, Henter I et al. (2010) Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatr 18: 293–303.

    Article  Google Scholar 

  43. Crane GE (1959): Cycloserine as an antidepressant agent. Am J Psychiatry 115:1025–1026.

    PubMed  CAS  Google Scholar 

  44. Vale S, Espejel MA, Dominguez JC (1971) Amantadine in depression. Lancet 2(7721): 437.

    Article  PubMed  CAS  Google Scholar 

  45. Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185: 1–10.

    Article  PubMed  CAS  Google Scholar 

  46. Davis BL (1982) The PCP epidemic: a critical review. Int J Addict 17: 1137–55.

    PubMed  CAS  Google Scholar 

  47. Berman RM, Cappiello A, Anand A et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatr 47: 351–4.

    Article  CAS  Google Scholar 

  48. Aan het Rot M, Collins KA, Murrough JW et al. (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatr 67: 139–45.

    Article  CAS  Google Scholar 

  49. Szuba MP, Baxter LR Jr, Altshuler LL et al. (1994) Lithium sustains the acute antidepressant effects of sleep deprivation: preliminary findings from a controlled study. Psychiatr Res 51: 283–95.

    Article  CAS  Google Scholar 

  50. Wu JC, Kelsoe JR, Schachat C et al. (2009) Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatr 66: 298–301.

    Article  CAS  Google Scholar 

  51. Wu JC, Buchsbaum M, Bunney WE Jr (2001) Clinical neurochemical implications of sleep deprivation’s effects on the anterior cingulate of depressed responders. Neuropsychopharmacology 25(5 Suppl): S74–8.

    Article  PubMed  CAS  Google Scholar 

  52. Gujar N, Yoo SS, Hu P, Walker MP (2011) Sleep deprivation amplifies reactivity of brain reward networks, biasing the appraisal of positive emotional experiences. J Neurosci 31: 4466–74.

    Article  PubMed  CAS  Google Scholar 

  53. Cirelli C (2002) How sleep deprivation affects gene expression in the brain: a review of recent findings. J Appl Physiol 92: 394–400.

    PubMed  CAS  Google Scholar 

  54. Ameisen O (2008) Le dernier verre. Paris: Denoël.

    Google Scholar 

  55. Colombo G, Agabio R, Carai MA et al. (2000) Ability of baclofen in reducing alcohol intake and withdrawal severity: I—Preclinical evidence. Alcohol Clin Exp Res 24: 58–66.

    PubMed  CAS  Google Scholar 

  56. Addolorato G, Caputo F, Capristo E et al. (2000) Ability of baclofen in reducing alcohol craving and intake: II—Preliminary clinical evidence. Alcohol Clin Exp Res 24: 67–71.

    PubMed  CAS  Google Scholar 

  57. Addolorato G, Caputo F, Capristo E et al. (2002) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37: 504–8.

    PubMed  CAS  Google Scholar 

  58. Addolorato G, Leggio L, Ferrulli A et al. (2007) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370: 1915–22.

    Article  PubMed  CAS  Google Scholar 

  59. Tyacke RJ, Lingford-Hughes A, Reed LJ, Nutt DJ (2010) GABAB receptors in addiction and its treatment. Adv Pharmacol 58: 373–96.

    Article  PubMed  CAS  Google Scholar 

  60. Edwards S, Kenna GA, Swift RM, Leggio l (2011) Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des 17: 1323–32.

    Article  PubMed  CAS  Google Scholar 

  61. Froestl W (2010) Chemistry and pharmacology of GABAB receptor ligands. Adv Pharmacol 58: 19–62.

    Article  PubMed  CAS  Google Scholar 

  62. Ameisen O (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: A self case-report of a physician. Alcohol Alcohol 40:47–50.

    Google Scholar 

  63. Ameisen O, de Beaurepaire R (2010) Suppression de la dépendance à l’alcool et de la consommation d’alcool par le baclofène à haute dose: un essai en ouvert. Ann Méd Psy 168: 159–62.

    Google Scholar 

  64. INSERM (2004) Psychothérapie, trois approches évaluées. Paris: éditions Inserm.

    Google Scholar 

  65. Herbert J, Lilienfeld S, Lohr J et al. (2000) Science and pseudoscience in the development of eye movement desensitization and reprocessing: implications for clinical psychology. Clin Psychol Rev 20: 945–71.

    Article  PubMed  CAS  Google Scholar 

  66. Davidson PR, Parker KC (2001) Eye movement desensitization and reprocessing (EMDR): a meta-analysis. J Consult Clin Psychol 69: 305–16.

    Article  PubMed  CAS  Google Scholar 

  67. Samara Z, Elzinga BM, Slagter HA, Nieuwenhuis S (2011) Do Horizontal Saccadic Eye Movements Increase Interhemispheric Coherence? Investigation of a Hypothesized Neural Mechanism Underlying EMDR. Front Psychiatry 9: 4.

    Google Scholar 

  68. Wolpe J (1975) Pratique de la thérapie comportementale. Paris: Masson.

    Google Scholar 

  69. Shapiro F (1989) Eye movement desensitization procedure: A new treatment for post-traumatic stress disorder. J Behav Ther Experiment Psychiatr 20: 211–7.

    Article  CAS  Google Scholar 

  70. Kabat-Zinn J (1990) Full Catastrophe Living: Using the Wisdom of your Body and Mind to Face Stress, Pain, and Illness. New York: Bantam Doubleday.

    Google Scholar 

  71. Bishop SR (2002) What do we really know about mindfulness-based stress reduction? Psychosom Med 64: 71–83.

    PubMed  Google Scholar 

  72. Fjorback LO, Arendt M, Ornbøl E et al. (2011) Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy–a systematic review of randomized controlled trials. Acta Psychiatr Scand 124: 102–19.

    Article  PubMed  CAS  Google Scholar 

  73. Chiesa A, Calati R, Serretti A (2011) Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. Clin Psychol Rev 31: 449–64.

    Article  PubMed  Google Scholar 

  74. Lutz A, Slagter HA, Dunne JD, Davidson RJ (2008) Attention regulation and monitoring in meditation. Trends Cogn Sci 12: 163–9.

    Article  PubMed  Google Scholar 

  75. Chambers R, Gullone E, Allen NB (2009) Mindful emotion regulation: An integrative review. Clin Psychol Rev 29: 560–72.

    Article  PubMed  Google Scholar 

  76. Teasdale JD, Segal ZV, Williams JM et al. (2000) Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 68: 615–23.

    Article  PubMed  CAS  Google Scholar 

  77. Kuyken W, Byford S, Taylor RS et al. (2008) Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 76: 966–78.

    Article  PubMed  Google Scholar 

  78. Segal ZV, Bieling P, Young T et al. (2010) Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatr 67: 1256–64.

    Article  PubMed  Google Scholar 

  79. Norberg MM, Krystal JH, Tolin DF (2008) A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatr 63: 1118–26.

    Article  CAS  Google Scholar 

  80. Lewis WC, Calden G, Thurston JR, Gilson WE (1957) Psychiatric and neurological reactions to cycloserine in the treatment of tuberculosis. Dis Chest 32: 172–82.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculté de Médecine, Université Paris Descartes, Paris 06, France

    Roland Dardennes

  2. CMME, Hôpital Sainte Anne, Paris 14, France

    Roland Dardennes

  3. CPN, Inserm U894, Hôpital Sainte-Anne, Paris 14, France

    Roland Dardennes & N. Al Anbar

  4. Université PMC, École Doctorale 158 “Cerveau-Cognition-Comportement”, Paris 05, France

    N. Al Anbar

Authors
  1. Roland Dardennes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Al Anbar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. CMME hôpital Sainte-Anne, 100, rue de la Santé, 75674, Paris cedex 14, France

    Frédéric Rouillon

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Dardennes, R., Al Anbar, N. (2012). Vraies et fausses innovations en psychiatrie. In: Rouillon, F. (eds) Psychiatrie française / Psychiatrie en France. Springer, Paris. https://doi.org/10.1007/978-2-8178-0299-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0299-2_8

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0298-5

  • Online ISBN: 978-2-8178-0299-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation